Novartis for Alcon (ACL)? Novartis Says "No" But Market Says "Yes"
Tweet
Share
E-mailGet Alerts ACL Hot Sheet
Join SI Premium – FREE
Alcon Inc. (NYSE: ACL) continues to tick higher on speculation Novartis (NYSE: NVS) could buyout the remaining shares they don't control.
A few days ago, UBS made a strong case for such a deal. Today another firm is making similar comments - FTN Equity. UBS said NVS can afford to pay $235.80 per minority share due to the $686 million in synergies a deal would create.
Novartis said they aren't in talks for such a deal, but investors think maybe they should be and are buying up the shares. Even after the denial the shares did not slow down much.
ACL is up 1.3% to $159.82.
A few days ago, UBS made a strong case for such a deal. Today another firm is making similar comments - FTN Equity. UBS said NVS can afford to pay $235.80 per minority share due to the $686 million in synergies a deal would create.
Novartis said they aren't in talks for such a deal, but investors think maybe they should be and are buying up the shares. Even after the denial the shares did not slow down much.
ACL is up 1.3% to $159.82.
You May Also Be Interested In
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Scorpion Capital says short Twist Biosciences
Create E-mail Alert Related Categories
Insiders' Blog, Rumors, Trader TalkRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
